肝癌微环境及其药物干预研究进展  

Research advances in hepatocellular carcinoma microenvironment and its pharmacological intervention

作　　者：崔敏[1] 刘清华[2] CUI Min;LIU Qing-Hua(The First Affiliated Hospital;Department of Oncology, The First Affiliated Hospital, Medical College, Shihezi University, Shihezi 832008, China)

机构地区：[1]石河子大学医学院第一附属医院,新疆石河子832008 [2]石河子大学医学院第一附属医院肿瘤内科,新疆石河子832008

出　　处：《转化医学电子杂志》2017年第11期73-78,共6页E-Journal of Translational Medicine

基　　金：石河子大学医学院第一附属医院院级课题(BS2015-062;TP2014-003)

摘　　要：肝癌(HCC)是一种较常见且恶性程度较高的消化系统恶性肿瘤.在HCC的发生、发展过程中,除了HCC细胞本身外,HCC微环境发挥着至关重要的作用.HCC微环境是HCC在其发生过程中所处的内环境,它由细胞成分和非细胞成分共同构成.细胞成分主要包括肝星状细胞、肿瘤相关成纤维细胞、肿瘤相关巨噬细胞、肿瘤相关免疫细胞、调节T细胞和肿瘤相关内皮细胞等;非细胞成分主要包括细胞外基质、胞外基质蛋白、酶类、炎症因子和细胞因子及其受体等.这些成分在HCC细胞的形成、增殖、侵袭、迁移、黏附等过程中均发挥着重要的调控作用.近年来,将HCC微环境作为潜在作用靶点已成为研究HCC癌前状态和肝细胞癌药物治疗的新方向和热点领域.目前,干预HCC微环境的药物主要包括抗纤维化、抗肿瘤血管生成和免疫调节药物等.Hepatocellular carcinoma（ HCC） is one of the most common highly malignant tumors in the digestive system. Besides HCC cells,the microenvironment also plays a key role both in hepatocarcinogenesis and its development. Meanwhile, HCC microenvironment is the very place that hepatocarcinogenesis occurs,which consists of both cell components and non-cell components. Cell components include hepatic stellate cells（ HSCs）,tumor-associated fibroblasts（ TAF）,tumor-associated macrophages（ TAM）,tumor-associated immune cells,regulatory T cells and tumor-associated endothelial cell（ TEC）,etc. While the non-cell components include extracellular matrix（ ECM）,extracellular matrix protein,enzymes,inflammatory factors,various cytokines and receptors,etc. These ingredients play an important regulatory role in the process of formation,proliferation,adhesion,migration and invasion of HCC cells. Recently,HCC microenvironment has been considered as a potential target for the cure of HCC. And the drug interventions nowadays mainly consist of antifibrosis agents,anti-tumor angiogenesis agents,and immune regulation agents,etc.

关 键 词：肝细胞癌 肿瘤微环境 药物干预 

分 类 号：R735.7[医药卫生—肿瘤]